BioLineRx Ltd.

biolinerx.com

High-Tech Company
Public Company

(TASE: BLRX), (NASDAQ CM: BLRX)

TECH VERTICALS

Biopharmaceuticals, Biotechnology, Cancer, Cardiology, Life Sciences, MedTech, Pharmaceuticals, Therapeutics

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2003
Number of Employees	50
Reg. Number:	abCDe

DESCRIPTION

BioLineRx is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA™ (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

TECHNOLOGY

BioLineRx provides the strategic development planning and execution needed to prepare promising compounds for introduction into the global arena. BioLineRx screens and selects compounds that have the greatest potential to produce safe, effective, approved and marketed drugs. Through our proprietary selection process, BioLineRx evaluates a compound's potential for success by looking at its technological novelty, patent status, market need and approvability.

Products and Phases

Product	Phase
BL-5010	CE Approved
BL-5010 is a customized, proprietary pen-like applicator containing a novel, acidic, aqueous solution for the non-surgical removal of skin lesions. In December 2014, BioLineRX entered into an exclusive out-licensing arrangement with Perrigo Company plc, or Perrigo, for the rights to BL-5010 for over-the-counter, or OTC, indications in Europe, Australia and additional selected countries.
Motixafortide (BL-8040) in HSC mobilization	Phase I
BioLineRx is advancing a Phase 1 clinical trial that will evaluate the safety and feasibility of motixafortide as monotherapy and in combination with natalizumab (VLA-4 inhibitor) to mobilize hematopoietic stem cells (HSCs) for gene therapy in patients with sickle cell disease (SCD).
Motixafortide (BL-8040) in cancer immunotherapy	Phase II
Motixafortide is also being evaluated in two randomized Phase 2b trials in combination with checkpoint inhibitor and chemotherapy as a first-line therapy in metastatic pancreatic cancer.
APHEXDA™	FDA Approved
APHEXDA is a prescription medication used with filgrastim* to move hematopoietic stem cells from the bone marrow to the peripheral blood for collection during apheresis and subsequent autologous transplantation in patients with multiple myeloma.

ESTIMATED ANNUAL SALES

	TARGET MARKETS
	Pharmaceutical Companies, Academic Institutions, Technology Transfer Offices

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
F1CA77DE-1F7A-E111-AC59-00155D32A403		BioLineRx Ltd.
	Subsidiary	iPharma	BioLineRx Ltd.

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm
abC Defghij	Investment Bank
abC Defghij	Law Firm

REMARKS

Date	Remark
01/07/2009	Ikaria Holdings Inc. has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040.
01/06/2007	BioLineRx and Pan Atlantic Bank and Trust have set up a joint $6m fund to support the Early Development Program (EDP), a unique program to identify and advance new and innovative therapeutic projects from the earliest stages, even before in vivo activity has been demonstrated.
	BioLineRx also operates BioLine Innovations Jerusalem (BIJ), a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates, which is the only Israeli biotech incubator supported by Office of Chief Scientist, Israeli Ministry of Industry, Trade and Labor

CONTACT INFO

Expand / Collapse All

Main Address: Modiin-Maccabim-Reut, Israel

Address	Modi’in Technology Park, 2 HaMa’ayan St.
City	Modiin-Maccabim-Reut
Country	Israel
Zip	7177871

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: Waltham, United States

City	Waltham
State/Province	MA
Country	United States

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Philip Serlin	CEO
Ms. Mali Zeevi	CFO
Dr. Ella Sorani	Chief Development Officer
Dr. Irit Gliko-Kabir	VP, Clinical Operations	Bioblast (Senior Director of Clinical Studies)
Dr. Bela Neiman	VP, Analytical Chemistry

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	Former VP, Head of Teva Innovative Ventures.
abC Defghij	Board Member	Chairman & CEO, Quark Pharmaceuticals
abC Defghij	Board Member	Former VP, The Jackson Laboratory
abC Defghij	Board Member	Former President & CEO, Hadasit
abC Defghij	Board Member	Owner, ARTA DAR
abC Defghij	Board Member	Managing Partner, Cross Atlantic Partners
abC Defghij	Board Member	VP R&D & Manufacturing, Gloria Biosciences
abC Defghij	External Director	Venture Partner, Forbion Capital Partners

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Apr. 01, 2024	Twelfth Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering of American Depositary Shares (ADSs) and warrants
Sep. 19, 2022	Eleventh Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering of ADS and associated warrants
Jan. 22, 2021	Tenth Public Offering	NASDAQ CM	abCDe	abCDe	Including $4.5m from the full exercise of the underwriter of its option to purchase additional shares (ADSs).
Jun. 01, 2020	Ninth Public Offering		abCDe	abCDe	Registered Direct Offering.
May. 26, 2020	Eighth Public Offering	NASDAQ CM	abCDe	abCDe	Offering of American Depositary Shares (ADSs).
Feb. 07, 2019	Seventh Public Offering	NASDAQ CM	abCDe	abCDe
Mar. 31, 2017	Sixth Public Offering	NASDAQ CM	abCDe	abCDe
Mar. 08, 2015	Fifth Public Offering	NASDAQ CM	abCDe	abCDe	Offering of American Depositary Shares (ADSs).
Mar. 08, 2014	Fourth Public Offering	NASDAQ CM	abCDe	abCDe
Jul. 24, 2011	Listing	NASDAQ CM	abCDe	abCDe	Through American Depositary Receipts (ADRs).
Dec. 29, 2009	Third Public Offering	TASE	abCDe	abCDe
Jul. 05, 2009	Second Public Offering	TASE	abCDe	abCDe	A rights issue was offered to the company's existing shareholders only. Among the excepting shareholders were Teva and Pan Atlantic.
Feb. 07, 2007	IPO	TASE	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Nov. 21, 2024

Initial Revenues

abCDe

Venture Lending

Sep. 15, 2022

Initial Revenues

abCDe

Debt Financing

Sep. 15, 2022

Initial Revenues

abCDe

Venture Lending

Oct. 03, 2018

R&D

abCDe

PIPE

Jul. 31, 2017

R&D

abCDe

PIPE

Dec. 17, 2014

R&D

abCDe

PIPE

May. 30, 2014

Revenue Growth

abCDe

PIPE

Feb. 12, 2013

R&D

abCDe

PIPE

Feb. 27, 2012

R&D

abCDe

Third Round

Jan. 10, 2007

R&D

abCDe

Second Round

Sep. 26, 2005

R&D

abCDe

First Round - Extended

May. 04, 2004

R&D

abCDe

Other

May. 28, 2003

R&D

abCDe

First Round

Apr. 08, 2003

R&D

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 05, 2007

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Other	abCDe

R&D Grant

May. 31, 2005

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Dec. 02, 2004

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

	Acquisitions made by BioLineRx

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Biomed...	Mar. 23, 2017	abCDe

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

iPharma

Biomed

Seed

01/08/2016

$1m

$2m

Exits (1)

Company Name		Exit Type	Date Announced	Amount	Remarks
abC Defghij		IPO	14/03/2014	abCDe

Last Updated:	abCDe
IVC Number:	abCDe